MétaCan
Menu
Back to cohort

P-105 Dermatologic Complications in Patients Treated with Certolizumab Pegol

2014· article· en· W2315302720 on OpenAlexaboutno aff
Lichtenstein Gary, Loftus Edward, Wolf Doug, Lee Scott, Randall Charles, Abraham Bincy, Choi Jennifer, Colombel Jean-Frédéric, Catherine Arendt, Golembesky Amanda, Sen David, Jason Coarse, Spearman Marshall, Gordana Kosutic

Bibliographic record

VenueInflammatory Bowel Diseases · 2014
Typearticle
Languageen
FieldMedicine
TopicAutoimmune Bullous Skin Diseases
Canadian institutionsnot available
Fundersnot available
KeywordsCertolizumab pegolMedicineAdverse effectInternal medicineDermatologyIncidence (geometry)PsoriasisSurgeryGastroenterologyTumor necrosis factor alphaAdalimumab

Abstract

fetched live from OpenAlex

Tumor necrosis factor (TNF) inhibitors have significantly changed the management of patients with inflammatory bowel diseases (IBD). Cutaneous reactions are among the most common adverse events (AEs) seen with anti-TNF therapy. Certolizumab pegol (CZP) is a subcutaneously (sc) administered PEGylated Fc-free Fab' fragment of a humanized TNF alpha monoclonal antibody. Dermatologic complications in patients using CZP are not fully described. The aim of this analysis was to assess the effect of CZP in patients with Crohn's disease (CD) on dermatologic complications of clinical interest, including immune-mediated complications (e.g., psoriasis and lupus-like syndrome). Pooled safety data including 2570 CZP-treated adult CD patients from 15 Phase 2 or 3 placebo (PBO)-controlled or open-label studies were analyzed. In the short-term, PBO-controlled studies 919 patients received CZP and 875 patients received PBO. Patients received CZP 400 mg sc every 4 weeks (74% of patients) or 400 mg every 2 weeks. The frequency and incidence rate (IR, events per 100 patient-years) of dermatologic complications were calculated for patients receiving PBO, CZP (in PBO-controlled, short-term studies), and CZP in all studies. The mean duration of CZP exposure was 568 days (approximately 1.6 years, range 14 days—7.7 years). The 2570 CZP-treated patients contributed to 4378 patient-years. For the PBO-controlled studies, there were 299 and 262 patient-years for the CZP and PBO groups, respectively. Demographics were similar for age, gender, race and BMI. Disease distribution, using the Montreal classification, disease behavior and history of prior surgical resections were also similar between the groups. Immunosuppressant and corticosteroid use was similar amongst the groups. In the PBO-controlled studies, the selected dermatologic complications occurred in 8/919 patients (0.87%) in the CZP group and 4/875 patients (0.46%) in the PBO group. One patient in the PBO group and 3 in the CZP group from the PBO-controlled studies developed psoriatic conditions. There were no cases of psoriasiform dermatitis, guttate psoriasis, or pustular psoriasis in any of the groups, nor any cases of skin vasculitides. There was 1 case of bullous conditions in the CZP group (0 in the PBO group). Alopecia occurred in 3 cases on PBO and 4 cases on CZP (of which 1 was attributed to alopecia areata). Alopecia totalis and madarosis were not observed. The long-term IR for the key dermatologic conditions did not appear to differ considerably from the CZP or PBO rates reported in the PBO-controlled studies (Table). Data from 2570 CD patients with 4378 patient-years of follow up suggest that CZP may not be associated with a high rate of dermatologic complications. The most common dermatologic adverse event was psoriasis. The IR for psoriatic conditions appeared to be nominally higher in the CZP group whereas the IR for skin vasculitis, bullous conditions and alopecia were similar between PBO and CZP in the PBO-controlled studies. These findings are favorable as there was minimal occurrence of dermatological complications.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.226
Teacher spread0.219 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueInflammatory Bowel DiseasesSame topicAutoimmune Bullous Skin DiseasesFrench-language works237,207